NICE numbers at 20: trends in deals

NICE provides a downloadable excel file of details of Technology Appraisal (TAs) recommendations which can help explore trends in deals that play a role in NICE recommendations made.

Blow to Novartis as NICE rejects migraine drug Aimovig again

NICE numbers at 20 – a closer look at cancer

There has been continual interest in what the UK’s Health Technology Assessment (HTA) agency, the National Institute for Health and Care Excellence (NICE), has said when it comes to cancer

HAE patients get new option as NICE backs Takeda's Takhzyro

Patients in England and Wales with hereditary angioedema (HAE) should soon have a new treatment option after NICE recommended Takeda’s Takhzyro (lanadelumab) should be funded by the NHS in

NHS funds eye gene therapy, after Novartis cuts £613,000 pri...

NICE has recommended the NHS should fund Novartis’ Luxturna for a rare eye disorder, after the company agreed a discount from the list price of more than £613,000 per patient.

NICE lowers threshold for blood pressure drugs in new guidan...